The Galway-based medical device developer Crospon is to launch its new imaging catheter for weight-loss surgery in the US in March.
Having received clearance from the US FDA, Crospon will launch the catheter at the SAGES 2011 Conference in San Antonio, Texas, in March.
As the latest development to Crospon’s EndoFLIP range, this catheter is designed to assist surgeons during sleeve gastrectomy and gastric imbrication procedures.
Speaking following the FDA approval, John O’Dea, CEO, Crospon, said: “We continue to see positive results with the intra-operative use of EndoFLIP during gastric banding. By providing surgeons for the first time with an ability to measure the size of the sleeve they are creating, in real-time during surgery, we believe it can increase the safety profile of the procedure by ensuring that the sleeve is not created too small, which in turn reduces the risk of leaks.“
Crospon develops leading-edge minimally invasive medical devices for monitoring, diagnosis and therapy in the gastroenterology area. In 2010, Crospon launched its EndoFLIP product in the US market at the 12th World Congress of Endoscopic Surgery in National Harbor, Washington DC.
The EndoFLIP product, which received FDA clearance in December 2009, allows a bariatric (weight-loss) surgeon to measure and set a consistent gastric band stomach size during surgery.
In January 2010, Crospon announced the completion of a €2m round of funding. It also spun out a new company, Janisys, to focus on the development of a drug-delivery platform that uses HP’s inkjet printing technology to enable painless, controlled drug release from a patch to the skin.
In 2009, Crospon announced the establishment of a US operation in Carlsbad, California.
Crospon was established in 2006 by O’Dea who had previously co-founded Caradyne, a respiratory products company that was acquired by Respironics in 2004.